Develops drugs for central nervous system diseases.
Jun 2026Revenue $57.6M/yrExpenses $65.9M/yr
No trend
Figures by year
When will Aytu Biopharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $57.6M and expenses $65.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Jun 2026 | $57.6M | $65.9M | −$8.31M |
| Jun 2025 | $66.4M | $74.2M | −$7.83M |
| Jun 2024 | $65.2M | $66.8M | −$1.59M |
| Jun 2023 | $107M | $124M | −$17.1M |
| Jun 2022 | $96.7M | $207M | −$110M |
| Jun 2021 | $65.6M | $125M | −$58.9M |
| Jun 2020 | $27.6M | $48.8M | −$21.1M |
| Jun 2019 | $7.32M | $24.2M | −$16.8M |
| Jun 2018 | $3.66M | $23.4M | −$19.7M |
| Jun 2017 | $3.22M | $23.3M | −$20.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.